TABLE 4

Fetuses from +/+ × Sp/+ and Sp/+ × +/+ maternal-diabetes matings determined to have the wild-type (+/+) or heterozygous (Sp/+) genotype

+/+ × Sp/+ 144 fetuses (30 litters)
Sp/+ × +/+ 63 fetuses (16 litters)
Wild-type (+/+)Heterozygote (Sp/+)Wild-type (+/+)Heterozygote (Sp/+)
Total fetuses per genotype 74 (51.4%) 70 (48.6%) 29 (46.0%) 34 (54.0%) 
Fetuses with exencephaly 14 (18.9%) 17 (24.3%) 12 (41.4%) 11 (32.4%) 
Fetuses with spina bifida 1 (1.4%) 10 (14.3%)* 3 (8.8%) 
+/+ × Sp/+ 144 fetuses (30 litters)
Sp/+ × +/+ 63 fetuses (16 litters)
Wild-type (+/+)Heterozygote (Sp/+)Wild-type (+/+)Heterozygote (Sp/+)
Total fetuses per genotype 74 (51.4%) 70 (48.6%) 29 (46.0%) 34 (54.0%) 
Fetuses with exencephaly 14 (18.9%) 17 (24.3%) 12 (41.4%) 11 (32.4%) 
Fetuses with spina bifida 1 (1.4%) 10 (14.3%)* 3 (8.8%) 

Percentages of NTDs secondary to ALX-induced (100 mg/kg intravenous) maternal diabetes in fetuses of each genotype are also presented.

*

χ2 indicates a significant association (P ≤ 0.05) between spina bifida and presence of the Sp allele.

Close Modal

or Create an Account

Close Modal
Close Modal